HealthAug 11, 2026
Epicrispr raises $90.0M (Aug 2026)
$90.0M
$90MGenerated social card
Headline
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease - BioPharma Dive
About
Epicrispr is focused on developing epigenetic editing therapies for rare muscle diseases. The company aims to leverage its innovative technology to address unmet medical needs in this niche market. The recent funding will help advance their drug development efforts.
Article summary
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease BioPharma Dive
Investors
Related rounds
| Aug 11, 2026 | K2 Therapeutics | $50.0M | Seed | Singapore |
| Aug 11, 2026 | Ayati Devices | $180K | — | India |
| Aug 09, 2026 | Curecreteconnect | $144.0M | — | India |
| Aug 09, 2026 | StairMed | $163.0M | — | China |